BIORIGEN S R L has a total of 11 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 2007. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Italy. Its main competitors in its focus markets biotechnology, medical technology and pharmaceuticals are BANC DE SANG I TEIXITS, IHEART JAPAN CORP and CELLTRAN LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 3 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | Italy | 2 | |
#4 | Australia | 1 | |
#5 | Canada | 1 | |
#6 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Medical technology | |
#3 | Pharmaceuticals | |
#4 | Agriculture |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Object sterilising | |
#3 | Therapeutic chemical compounds | |
#4 | Animal care | |
#5 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Mastrogiacomo Maddalena | 9 |
#2 | Cancedda Ranieri | 9 |
#3 | Muraglia Anita | 5 |
#4 | Scala Marco | 4 |
#5 | Migliaresi Claudio | 2 |
#6 | Motta Antonella | 2 |
#7 | Nguyen Van Thi | 2 |
#8 | Pagano Aldo | 2 |
#9 | Lorandi Christian | 2 |
#10 | Torre Maria Luisa | 1 |
Publication | Filing date | Title |
---|---|---|
WO2018162740A2 | Cell culture supplements | |
EP2574350A1 | Medical uses of lyophilized polymeric membranes containing blood derivatives | |
EP2574349A1 | Therapeutic use of gelatin hydrogels with a gel-sol transition at body temperature | |
EP2152873A2 | Gene expression regulation technology and noncoding rnas for diagnosis and therapy | |
CA2653546A1 | Bio-membrane for tissue regeneration |